Who is the top 10 BP in FimaNac (a theory!!)

Stock DZ
10.07.2018 kl 13:46
1772

Dette er en arkivert tråd!
Hi

Many of us in this forum think that AstraZeneca is the top 10 BP in FimaNac collaboration. The reason was mainly the appointment of Professor Andrew Hughes in our board. However what I am publishing now here could only consolidate this thought and if we read between the lines we would know why this 10 BP is secretive about it. (again this is a theory).

please go to this presentation in the link below and go to pages 81 and 82 (which i am copying below as well).

https://www.astrazeneca.com/content/dam/az/PDF/2017/IMED_Annual%20Review%202017_FINAL%20APPROVED.pdf


Page 81: the profile of James Douglas, Senior Scientist is very intersting to us as he has experience with photo-chemistry

"Early Chemical Development James is a senior scientist in Early Chemical Development, focussed on the synthesis of drug substance to support multiple projects as they progress through clinical trials. He has recently joined the company after time in academia (University of St Andrews, Boston University, and the University of Michigan) and the pharmaceutical industry in both the UK and the US, becoming a leader in the application of visible light photochemistry to drug molecule synthesis. James has a special interest in the efficient construction of complex molecules and the application of new technology to this field. Most recently, James has been part of a specialised team tasked with the synthesis of especially challenging molecules, ones where successful manufacture is vital to the rapid development of potentially new medicines.

page 82: I think this is in line with FimaNac mission

Capitalise on new opportunities by understanding more about delivering macromolecules into cells

"We established a new team within Pharmaceutical Sciences to focus on addressing the challenges of delivering macromolecules into cells. This has included the recruitment of new scientific leadership positions in cell biology. The challenges of delivering macromolecules are multifaceted and include novel excipient design and synthesis, manufacture of carrier systems and understanding biological mechanisms of cellular uptake/trafficking. The Intracellular Delivery Team therefore worked holistically, in partnership with colleagues in Pharmaceutical Sciences and IMED functions, to form a multidisciplinary team which is uniquely positioned to tackle these challenges. The team brings together scientists with expertise in chemistry, formulation and bioscience and is focussed on advancing our scientific understanding of intracellular delivery for new modalities, such as modified mRNA and antisense oligonucleotides. The activities in the team will result in better research tools, new formulations and novel delivery approaches which will enable and enhance therapeutic programmes where intracellular delivery of macromolecules is needed. This in turn will allow us to work with previously undruggable targets, significantly increasing the biological breadth of our portfolio"
Redigert 10.07.2018 kl 13:47 Arkivert